Key clinical point: The 21-gene assay recurrence score is an independent predictor of locoregional recurrence in postmenopausal patients with node-positive breast cancer.
Major finding: Having intermediate or high recurrence scores was a significant predictor of locoregional recurrence in a multivariable analysis, with a hazard ratio of 2.36 (P = .04).
Study details: A retrospective analysis of 316 patients from a phase 3 study
Disclosures: This research was funded by the National Cancer Institute of Canada, Canadian Cancer Society, and Genomic Health, which markets the 21-gene assay OncotypeDX. Dr. Woodward disclosed receiving personal fees from Genomic Health outside this research as well as an advisory fee from Merck.
Woodward WA et al. JAMA Oncol. 2020 Jan 9. doi: 10.1001/jamaoncol.2019.5559.